Joseph R. Taylor

发表

Eleven amino acid glucagon-like peptide-1 receptor agonists with antidiabetic activity.

K. Constantine, R. Stoffel, B. Koplowitz, 2009, Journal of medicinal chemistry.

Dapagliflozin, a Selective SGLT2 Inhibitor, Improves Glucose Homeostasis in Normal and Diabetic Rats

Li Xin, Joseph R. Taylor, Songping Han, 2008, Diabetes.

Discovery of a Partial Glucokinase Activator Clinical Candidate: Diethyl ((3-(3-((5-(Azetidine-1-carbonyl)pyrazin-2-yl)oxy)-5-isopropoxybenzamido)-1H-pyrazol-1-yl)methyl)phosphonate (BMS-820132).

Steven A. Spronk, K. Behnia, J. Barrish, 2022, Journal of medicinal chemistry.

VPA-985, a nonpeptide orally active and selective vasopressin V2 receptor antagonist.

J. Taylor, Joseph R. Taylor, J. Dusza, 1998, Advances in experimental medicine and biology.

11b-Hydroxysteroid Dehydrogenase Type 1 Gene Knockout Attenuates Atherosclerosis and In Vivo Foam Cell Formation in Hyperlipidemic apoE Mice

Wen-pin Yang, Rongan Zhang, P. Gargalovic, 2013 .

Discovery of an Oxycyclohexyl Acid Lysophosphatidic Acid Receptor 1 (LPA1) Antagonist BMS-986278 for the Treatment of Pulmonary Fibrotic Diseases.

C. Chu, S. Jusuf, Yanou Yang, 2021, Journal of medicinal chemistry.

Discovery of 3-hydroxy-4-cyano-isoquinolines as novel, potent, and selective inhibitors of human 11β-hydroxydehydrogenase 1 (11β-HSD1).

S. Sheriff, R. Seethala, A. Nayeem, 2011, Bioorganic & medicinal chemistry letters.

Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.

W. Humphreys, O. Flint, E. Janovitz, 2008, Journal of medicinal chemistry.

Discovery of Clinical Candidate 2-((2S,6S)-2-Phenyl-6-hydroxyadamantan-2-yl)-1-(3'-hydroxyazetidin-1-yl)ethanone [BMS-816336], an Orally Active Novel Selective 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor.

David K. Leahy, J. Barrish, M. Kirby, 2017, Journal of medicinal chemistry.

Optimization of 1,2,4-Triazolopyridines as Inhibitors of Human 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD-1).

S. Sheriff, R. Seethala, A. Nayeem, 2014, ACS Medicinal Chemistry Letters.

Discovery of Clinical Candidate BMS-823778 as an Inhibitor of Human 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD-1).

S. Sheriff, R. Seethala, A. Nayeem, 2018, ACS medicinal chemistry letters.

Eleven amino acid glucagon-like peptide-1 receptor agonists with antidiabetic activity.

K. Constantine, R. Stoffel, B. Koplowitz, 2009, Journal of medicinal chemistry.